Changes in Total Lymphocyte Count as a Surrogate for Changes in CD4 Count Following Initiation of HAART: Implications for Monitoring in Resource-Limited Settings
- 1 May 2004
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 36 (1), 567-575
- https://doi.org/10.1097/00126334-200405010-00004
Abstract
A major obstacle to the administration of highly active antiretroviral therapy (HAART) in resource-limited settings is the high cost of CD4 count testing. The total lymphocyte count (TLC) has been proposed as a surrogate marker to monitor immune response to therapy. To assess, in a developed country setting, the capability and clinical utility of TLC change as a surrogate marker for CD4 count change in monitoring patients on HAART. Longitudinal co-variation between changes in TLC and concomitant changes in CD4 count following the initiation of HAART was examined using a retrospective cohort study of 126 HIV-positive patients attending The Miriam Hospital, Brown University, Providence, RI. Analyses included evaluation of the direction of TLC change as a marker for direction of CD4 change, using sensitivity and specificity; evaluation of absolute change in TLC as a marker for benchmark changes in CD4 (≥50 over 6 months, ≥100 over 12 months), using receiver-operator characteristic (ROC) curves; and a regression model of change in TLC as a function of change in CD4, to understand within-individual variation of longitudinal TLC measures. In the first 24 months of HAART, the sensitivity of a TLC increase as a marker for CD4 count increase over the same time period ranged from 86–94%, and the specificity ranged from 80–85%. The median change in TLC among patients with a CD4 count rise of ≥100 cells/mm3 at 1 year of HAART was +766 cells/mm3 while that of patients with a CD4 count rise of 3 Within the first 2 years of HAART, the direction of change in TLC appears to be a strong marker for direction of concomitant change in CD4 count (sensitivity 86–94% and specificity 80–85%, depending on length of interval). Positive and negative predictive values depend on the proportion of CD4 changes that are positive. In this cohort, that proportion is 87.9%, which yields high positive predictive value (96–98%) but lower negative predictive value (43–63%). Findings from the regression model suggest that taking multiple measurements of TLC at more frequent intervals may reduce variability and potentially improve predictive accuracy.Keywords
This publication has 26 references indexed in Scilit:
- Total Lymphocyte Count (TLC) Is a Useful Tool for the Timing of Opportunistic Infection Prophylaxis in India and Other Resource-Constrained CountriesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Monitoring HIV treatment in the developing world.The Lancet Infectious Diseases, 2002
- Antiretroviral treatment in resource-poor settings: clinical research prioritiesThe Lancet, 2002
- Cheaper HIV drugs for poor nations bring a new challenge: monitoring treatment.JAMA, 2002
- The High Cost of PovertyScience, 2002
- Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendationsAIDS, 2001
- Correlation between total and CD4 lymphocyte counts in HIV infection: not making the good an enemy of the not so perfectInternational Journal of STD & AIDS, 1996
- CD4 and total lymphocyte counts as predictors of HIV disease progressionQJM: An International Journal of Medicine, 1996
- Total Lymphocyte Count as a Predictor of Absolute CD4+ Count and CD4+ Percentage in HIV-lnfected PersonsPublished by American Medical Association (AMA) ,1993
- Application of the World Health Organization system for HIV infection in a cohort of homosexual men in developing a prognostically meaningful staging systemAIDS, 1992